ReviewMolecular therapy. Oncology2025
Regulation of the brain tumor microenvironment by focused ultrasound.
Review in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026.Cells · 2026Review
- Synergy of radiotherapy, focused ultrasound, and immunotherapy in the treatment of brain metastases.Journal of neuro-oncology · 2025Review
- ASMase Activation in Ultrasound-Stimulated Radiation Enhancement Using MRI-Guided Focused Ultrasound.Cells · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma and other high-grade primary malignant brain tumors are a serious threat to the life and health of patients; consequently, their accurate diagnosis and treatment are crucial. Brain tumors are usually treated by surgical resection, radiotherapy and drug chemotherapy; however, such treatments have side effects such as trauma, infection, and radiation exposure. Furthermore, owing to limitations in conditions such as the skull and blood-brain barrier, noninvasive treatment and diagnosis of brain tumors have been challenging. In recent years, focused ultrasound (FUS) technology has shown great advantages and application potential because of its noninvasive and energy-focusing characteristics in brain tumors. From the perspective of the brain tumor microenvironment, FUS can produce mechanical and thermal effects by delivering sound waves to brain tissue; these sound waves can induce blood-brain barrier opening, radiation sensitization, targeted substance delivery, immune enhancement, angiogenesis and destruction, oxidative stress, interstitial hydraulic regulation, and brain tumor marker sonobiopsy. The feasibility and safety data from both animal models and clinical trials support FUS as having great potential for use in the diagnosis and treatment of brain tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.